I slutningen af det 1. år (uge 54) var omkring 1053 patienter randomiseret igen til enten at forsætte samme behandling eller ophøre behandling efter uge 102.
At the end of the first year (week 54), 1053 patients were re-randomized to either continue or discontinue treatment through week 102.